While breast and prostate cancer are diagnosed more often in the U.S. each year, lung cancer (LC) is the most deadly. “Lung cancer causes more deaths than the next three most common cancers combined (colon, breast and prostate). An estimated 160,340 Americans were expected to die from lung cancer in 2012, accounting for approximately 28 percent of all cancer deaths.“ (ACS).” Consider breakthrough therapies for lung cancer.
However, this may be changing. The articles linked below use words like “revolutionary,” “game changing” and “breakthrough” to describe lung cancer therapies being developed in the United States in the past decade.
Make no mistake, lung cancer in all its forms and genetic variations is a complicated cancer. Therapies must be more personal and therefore require elaborate diagnostic testing. But there is hope for the lung cancer patient.
Your challenge is to know what you don’t know. That’s where I come in. I am a survivor of a different yet equally challenging cancer. I work with cancer patients to identify both conventional and non-conventional therapies and beyond…
Have you been diagnosed with lung cancer? What stage? What therapies are you considering? Scroll down the page, post a question or comment and I will reply to you ASAP.
“This genetic test is the result of a joint research of Computational Intelligence Group of the Department of Artificial Intelligence of the UPM with the Molecular Oncology Unit of the CIEMAT. This test would enhance patients’ quality of life for those who have a good prognosis by avoiding chemotherapy as well as being a cost saving for hospitals.”
“Ms. Carey has one of at least 15 LC variations, almost all of which scientists didn’t know existed 10 years ago. Researchers have identified those variations, most of them in just the past four years, by decoding DNA in tumors—akin to how crime labs analyze DNA to genetically fingerprint suspects…
The newfound variants have led major cancer centers to revamp their approach to treating cancer and have spurred a rush among drug companies to find medicines that narrowly target each one. The drugs don’t cure cancer and face significant hurdles. But doctors now talk of a “precision medicine” approach in which those pinpoint drugs can treat tumors far more effectively than catchall chemotherapy.”
“A new immunotherapy, MPDL3280A (under development by Genentech), has shown impressive results in a small group of patients with heavily pretreated nonsmall-cell lung cancer (NSCLC) who were taking part in a phase 1 clinical trial.
All but 1 of the 53 NSCLC patients responded, and the responses are “outstandingly durable,” Responses were higher in patients who were smokers than in nonsmokers — the first time that this has been seen with any therapy…”